Antithrombin III deficiency

Blood Reviews

Volumn 2, Issue 4, 1988, Pages 239-250

  Beresford, C H ^a  

^a UNIVERSITY OF OTAGO   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

HEPARIN;

ANTITHROMBIN III DEFICIENCY; HEREDITY; HUMAN; INHERITANCE; REVIEW; THROMBOEMBOLISM;

ANTITHROMBIN III DEFICIENCY; HUMAN; THROMBOEMBOLISM;

EID: 0024245618     PISSN: 0268960X     EISSN: None     Source Type: Journal    
DOI: 10.1016/0268-960X(88)90013-6     Document Type: Article

References (102)

1. Inherited antithrombin deficiency causing thrombophilia
2. Monocyte chemotaxis: stimulation by specific exosite region in thrombin
3. Familial AT III deficiency
4. Antithrombins and related inhibitors of coagulation
5. Actions and interaction of antithrombin and heparin
6. Congenital deficiencies of anticoagulant proteins
7. Antithrombin III mangel und thromboseneigung
8. Purification and partial characterisation of a hereditary abnormal antithrombin III fraction of a patient with recurrent thrombophelebitis
9. A new case of abnormal antithrombin III: biological characteristics and thromboembolic accidents management
10. Familial antithrombin III deficiency associated with recurrent arterial thromboembolism
11. Haemostatic system changes induced by 50 μg and 30 μg oestrogen/progestogen oral contraceptives. Modification of oestrogen effects by levonorgestrel
12. The effect of different hormonal approaches in the treatment of prostatic cancer on the plasma antithrombin III activity
13. Platelet and coagulation factors in proliferative diabetic retinopathy
14. Surgery, venous thrombosis and anti-Xa
15. Antithrombin in infancy and childhood
16. Antithrombine III durant la grossesse et aprés l'accouchement
17. Effect of heparin on antithrombin III activity during delivery and early puerperium
18. Antithrombins in childhood malnutrition
19. Verlust von inhibioren des gerinnungs systems bei der exsudative enteropathie
20. Haemostatic alterations in inflammatory bowel disease: response to therapy
21. Antithrombin III—verminderung nach perativer dunndarmansschaltung
22. Thrombophilie bei erworbenem anithrombin-III-mangel von patienten mit nephrotischem syndrom
23. Antithrombin III and diseases
24. Alterations of haemostasis associated with malignancy: etiology, pathophysiology, diagnosis and management
25. Molecular subunits and transamidase activity of Factor XIII during disseminated intravascular coagulation in acute leukaemia
26. Comparison of progressive antithrombin and the concentration of three thrombin inhibitors in human plasma
27. Antithrombin III: clinical significance
28. Thromboembolic complications associated with L-asparaginase therapy
29. The effect of total hip replacement and general surgery on antithrombin III in relation to venous thrombosis
30. Human hepatoma cells secrete single chain factor X, prothrombin and antithrombin III
31. Antithrombin III in fresh and cultured human endothelial cells—a natural anticoagulant from the vascular endothelium
32. On the molar antithrombin III concentration in normal human plasma
33. Isolation and sequence characterisation of a cDNA clone of human antithrombin III
34. 1-antitrypsin and antithrombin III
35. 1-antitrypsin from hydroxylamine cleavage: homology with antithrombin III
36. 1-proteinase inhibitor
37. 1-antitrypsin Pittsburgh (358 Met → Arg). A fatal bleeding disorder
38. 1-antitrypsin, antithrombin and the mechanism of inflammatory thrombosis
39. Crystallographic investigation of antithrombin III
40. The heparin binding site of antithrombin III—evidence for a critical tryptophan residue
41. Isolation and characterisation of a hereditary abnormal antithrombin III ‘antithrombin III Toyama’
42. Antithrombin III Toyama: replacement of arginine-47 by cysteine in hereditary abnormal antithrombin III that lacks heparin-binding ability
43. Interaction between cultured endothelial cells and abnormal antithrombin III ‘Toyama’
44. Antithrombin Rouen I (47 Arg → His) and Rouen II (47 Arg → Ser): two new variants with decreased heparin affinity
45. The site in human antithrombin for functional proteolytic cleavage by human thrombin
46. 1 reactive site variant with increased heparin affinity but no thrombin inhibitory activity
47. Antithrombin III Denver, A Ser to Leu 394 variant without protease inhibitory activity
48. Abnormal turnover of AT III Denver
49. Molecular genetic survey of 16 kindreds with hereditary antithrombin III deficiency
50. Antithrombin confirmation and the catalytic role of heparin
51. Fractionation of low molecular-weight heparin species and their interaction with antithrombin
52. Role of ternary complexes, in which heparin binds both antithrombin and proteinase, in the acceleration of the reactions between antithrombin and thrombin or factor Xa
53. Histidine-rich glycoprotein modulation of anticoagulant effect of heparin
54. Rabbit plasma inhibitor of the activated species of blood coagulation factor X: purification and some properties
55. Inhibition of human factor IXa by human antithrombinheparin cofactor
56. An anticoagulant action of heparin
57. Inhibition of activated factor XII by antithrombin-heparin cofactor
58. Progressive inactivation of purified factor VII by heparin and antithrombin III
59. Human plasma protein C isolation, characterisation and mechanism of activation by α-thrombin
60. Biological properties of the naturally occurring plasma inhibitor to activate factor X
61. Bioregulatory functions of thrombin
62. The physiological antithrombin (beta) variant with increased heparin affinity lacks carbohydrate at Asn 135
63. Antithrombin III biodistribution in healthy volunteers
64. Elimination of intravenous administered radiolabelled antithrombin III and heparin in humans
65. Metabolism of antithrombin III (heparin cofactor) in man: effects of venous thrombosis and heparin administration
66. Antithrombin III replacement therapy in patients with congenital and acquired antithrombin III deficiency
67. Pharmacokinetic analysis of infused antithrombin III concentrate and its application to the antithrombin III deficient patients
68. a new familial variant of antithrombin III: ‘antithrombin III Paris’
69. Antithrombin III Trento
70. Assignment of the human antithrombin III structural gene to chromosome 1q23-q25
71. Cloning and expression of the endogenous anticoagulant protein, human antithrombin III
72. Confirmation of linkage between AT III and Duffy blood group and assignment of AT III to 1q23-q25
73. Molecular heterogeneity of inherited antithrombin III deficiency
74. Characterisation of unusual DNA length polymorphism 5′ to the human antithrombin III gene
75. Hereditary thrombosis in a Utah Kindred is caused by a dysfunctional antithrombin III gene
76. Identification and characterization of a new antithrombin III familial variant (AT III Dublin) with possible increased frequency in children with canc
77. A method of antithrombin estimation using plasma defibrinated with ancrod
78. Methods for semi-micro or automated determination of thrombin, antithrombin and heparin cofactor using the substrate, H-D-Phe-Pip-Arg-p-nitroanilide-2HCL
79. Antithrombin (heparin cofactor) assay with ‘new’ chromogenic substrates (S-2238 and chromozym TH)
80. Antithrombin III. I. Evaluation of an automated antithrombin III method
81. Methodological considerations in antithrombin determination
82. An international collaborative study establishing a reference preparation for antithrombin III
83. Immunochemical quantitation of antigens by single radial immunodiffusion
84. Electroimmunoassay
85. Further investigations on antithrombin III in the plasmas of patients with the abnormality of antithrombin III Budapest
86. Different forms of AT-III congenital defect: a study by crossed immunoelectrofocusing
87. Analysis of antithrombin III microheterogeneity by isoelectric focusing in polyacrylamide gels and immunoblotting
88. 2-antiplasmin in plasma by laser nephelometry
89. Laser nephelometric quantitation of antithrombin III, development of a new assay
90. The determination of antithrombin III by radioimmunoassay and its clinical application
91. New methods in haemostatic testing
92. Monitoring plasma antithrombin III during infusion of antithrombin III concentrate
93. Treatment of acute thrombosis in cases of antithrombin III deficiency
94. Stanazolol treatment in an AT III deficient patient
95. Familial antithrombin III deficiency
96. Pregnancy and congenital deficiency in antithrombin III or protein C
97. Treatment of Congenital Thrombotic Syndromes
98. Prophylaxis of thromboembolism during pregnancy in three sisters with congenital antithrombin III deficiency
99. Defects in serine protease inhibitors
100. 1-proteinase inhibitor